查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1592907

流感诊断市场：按测试类型、最终用户划分 - 2025-2030 年全球预测

Influenza Diagnostics Market by Test Type (Cell Culture, Rapid Influenza Diagnostic Tests, Reverse Transcription-Polymerase Chain Reaction), End-User (Hospitals, Laboratories, Point-Of-Care Testing) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年流感诊断市值为12亿美元，预计2024年将达13.2亿美元，复合年增长率为9.86%，预计到2030年将达到23.2亿美元。

流感诊断市场包括识别流感病毒感染的工具和流程。这项需求源自于流感病毒的全球大流行，流感病毒每年都会导致严重的发病率和死亡率。快速、准确的诊断对于病例管理、流行病学监测和疫情预防至关重要。这些诊断的应用涵盖医院、诊所、诊断实验室和研究机构，对于指南临床决策、管理公共卫生反应和开发疫苗至关重要。此外，一些流感病毒株感染疾病的，因此最终用途包括人类保健和兽医应用。

主要市场统计
基准年[2023] 12亿美元
预测年份 [2024] 13.2亿美元
预测年份 [2030] 23.2亿美元
复合年增长率（%） 9.86%

流感诊断市场的主要成长要素包括技术进步、对就地检验需求的增加以及由于最近的流行病而引起的对感染疾病的日益关注。人口老化和慢性呼吸道疾病盛行率上升将进一步推动需求，推动市场强劲成长。市场开拓机会包括开发可以同时检测多种病原体、提高效率和患者治疗效果的多重诊断平台。公司可以利用向新兴市场扩张的机会，这些市场的医疗保健基础设施的改善正在增加获得诊断的机会。

然而，市场成长面临的挑战包括先进诊断的高价格、某些地区的保险报销有限以及需要熟练的专业人员操作复杂的诊断设备。此外，流感病毒的快速突变使有效诊断的开发变得复杂。创新机会在于开发更快、更具成本效益和更易于使用的诊断解决方案，例如使用 CRISPR 技术和纸基生物感测器的解决方案。此外，整合人工智慧来提高诊断准确性和预测流感爆发为研究和业务成长提供了一个有前景的领域。市场的特点是技术快速发展、竞争激烈，需要持续创新和策略联盟来保持竞争力。

市场动态：快速发展的流感诊断市场的关键市场洞察

供需的动态交互作用正在改变流感诊断市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 流感流行和流感筛检检测增加
    • 增加流感诊断研究经费
    • 提高使用特定诊断测试进行早期检测和诊断的意识
  • 市场限制因素
    • 核准新诊断测试的严格法律规范
  • 市场机会
    • 开发先进的诊断测试，例如 CLIA 豁免的 POC 分子流感测试
    • 拥有强大的经销网络
  • 市场挑战
    • 医疗费用上涨

波特五力：驾驭流感诊断市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解流感诊断市场的外部影响

外部宏观环境因素在塑造流感诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解流感诊断市场的竞争状况

对流感诊断市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

流感诊断市场中的 FPNV 定位矩阵供应商绩效评估

FPNV定位矩阵是评估流感诊断市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘流感诊断市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对流感诊断市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 流感流行和流感筛检检测增加
      • 增加流感诊断研究经费
      • 透过特定的诊断测试提高早期检测和快速诊断的意识
    • 抑制因素
      • 核准新诊断测试的严格法规结构
    • 机会
      • 开发先进的诊断测试，例如 CLIA 豁免的 POC 分子流感测试
      • 强大的分销网络的可用性
    • 任务
      • 医疗费用上涨
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按测试类型分類的流感诊断市场

  • 细胞培养
  • 流感快速诊断检测
  • 逆转录聚合酵素链锁反应

第七章流感诊断市场：依最终使用者分类

  • 医院
  • 研究所
  • 就地检验

第八章美洲流感诊断市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区流感诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲的流感诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Aetna Inc.
  • Becton, Dickinson and Company
  • Cepheid
  • Co-Diagnostics, Inc.
  • DIASORIN MOLECULAR LLC
  • F. Hoffmann-La Roche Ltd.
  • Luminex Corporation
  • Merck KGaA
  • Quidel Corporation
  • SA Scientific Ltd.
  • Sansure Biotech Inc.
  • Secure Diagnostics Pvt. Ltd.
  • Sekisui Diagnostics, LLC
  • Thermo Fisher Scientific Inc.
Product Code: MRR-43127F72796F

The Influenza Diagnostics Market was valued at USD 1.20 billion in 2023, expected to reach USD 1.32 billion in 2024, and is projected to grow at a CAGR of 9.86%, to USD 2.32 billion by 2030.

The influenza diagnostics market involves tools and processes used to identify influenza virus infections. Its necessity stems from the global prevalence of the influenza virus, which causes significant morbidity and mortality annually. Rapid and accurate diagnostics are crucial for patient management, epidemiological surveillance, and the prevention of outbreaks. The application of these diagnostics spans hospitals, clinics, diagnostic laboratories, and research institutions, where they are essential for guiding clinical decisions, managing public health responses, and developing vaccines. Additionally, their end-use includes both human healthcare and veterinary applications, given the zoonotic nature of some influenza strains.

KEY MARKET STATISTICS
Base Year [2023] USD 1.20 billion
Estimated Year [2024] USD 1.32 billion
Forecast Year [2030] USD 2.32 billion
CAGR (%) 9.86%

Key growth factors in the influenza diagnostics market include technological advancements, increased demand for point-of-care testing, and a heightened focus on infectious diseases due to recent pandemics. The aging population and the rising incidence of chronic respiratory diseases further drive demand, positioning the market for robust growth. Opportunities in the market include the development of multiplex diagnostic platforms that can simultaneously test for multiple pathogens, enhancing efficiency and patient outcomes. Companies can capitalize on expanding into emerging markets where healthcare infrastructure improvements are increasing access to diagnostics.

However, market growth may be challenged by the high cost of advanced diagnostics, limited reimbursement in certain regions, and the need for skilled professionals to operate complex diagnostic equipment. Additionally, the rapid mutation of influenza viruses can complicate the development of effective diagnostics. Innovation opportunities lie in the development of faster, more cost-effective, and user-friendly diagnostic solutions, such as those using CRISPR technology or paper-based biosensors. Moreover, integrating artificial intelligence to improve diagnostic accuracy and predict influenza outbreaks offers a promising area for research and business growth. The market is characterized by rapid technological evolution and competitive intensity, necessitating continuous innovation and strategic partnerships to maintain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Influenza Diagnostics Market

The Influenza Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of influenza and increasing number of influenza screening test
    • Growth in research funding for influenza diagnostics
    • Growing awareness for early detection faster diagnosis using specific diagnostic tests
  • Market Restraints
    • Stringent regulatory framework for the approval of new diagnostic tests
  • Market Opportunities
    • Development of advanced diagnosis test such as CLIA-waived POC molecular influenza tests
    • Availability of strong distribution network
  • Market Challenges
    • Rising healthcare costs

Porter's Five Forces: A Strategic Tool for Navigating the Influenza Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Influenza Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Influenza Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Influenza Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Influenza Diagnostics Market

A detailed market share analysis in the Influenza Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Influenza Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Influenza Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Influenza Diagnostics Market

A strategic analysis of the Influenza Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Influenza Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aetna Inc., Becton, Dickinson and Company, Cepheid, Co-Diagnostics, Inc., DIASORIN MOLECULAR LLC, F. Hoffmann-La Roche Ltd., Luminex Corporation, Merck KGaA, Quidel Corporation, SA Scientific Ltd., Sansure Biotech Inc., Secure Diagnostics Pvt. Ltd., Sekisui Diagnostics, LLC, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Influenza Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Cell Culture, Rapid Influenza Diagnostic Tests, and Reverse Transcription-Polymerase Chain Reaction.
  • Based on End-User, market is studied across Hospitals, Laboratories, and Point-Of-Care Testing.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of influenza and increasing number of influenza screening test
      • 5.1.1.2. Growth in research funding for influenza diagnostics
      • 5.1.1.3. Growing awareness for early detection faster diagnosis using specific diagnostic tests
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory framework for the approval of new diagnostic tests
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of advanced diagnosis test such as CLIA-waived POC molecular influenza tests
      • 5.1.3.2. Availability of strong distribution network
    • 5.1.4. Challenges
      • 5.1.4.1. Rising healthcare costs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Influenza Diagnostics Market, by Test Type

  • 6.1. Introduction
  • 6.2. Cell Culture
  • 6.3. Rapid Influenza Diagnostic Tests
  • 6.4. Reverse Transcription-Polymerase Chain Reaction

7. Influenza Diagnostics Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Laboratories
  • 7.4. Point-Of-Care Testing

8. Americas Influenza Diagnostics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Influenza Diagnostics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Influenza Diagnostics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Aetna Inc.
  • 3. Becton, Dickinson and Company
  • 4. Cepheid
  • 5. Co-Diagnostics, Inc.
  • 6. DIASORIN MOLECULAR LLC
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Luminex Corporation
  • 9. Merck KGaA
  • 10. Quidel Corporation
  • 11. SA Scientific Ltd.
  • 12. Sansure Biotech Inc.
  • 13. Secure Diagnostics Pvt. Ltd.
  • 14. Sekisui Diagnostics, LLC
  • 15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. INFLUENZA DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. INFLUENZA DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. INFLUENZA DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INFLUENZA DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INFLUENZA DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID INFLUENZA DIAGNOSTIC TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. INFLUENZA DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023